Business Context and Reporting Period
This Form 8-K is filed by Moleculin Biotech, Inc. (MBRX) on January 7, 2026. The report addresses a significant corporate governance event regarding the company's continued listing status on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on regulatory compliance status rather than financial performance metrics.
Material Changes
The primary material change reported is the resolution of a delisting threat. Previously, the company failed to meet Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity of $2.5 million. On January 6, 2026, Nasdaq staff confirmed the company has regained compliance with this rule and all applicable continued listing standards.
Outlook and Management Commentary
Management confirmed that the hearing panel appeal regarding the delisting determination has been cancelled following the confirmation of compliance. The company is now in good standing with Nasdaq listing requirements. No forward-looking guidance or discussion of risks beyond the resolved listing issue is provided in this specific filing.
Investor Verification Checklist
- Verify the specific actions taken by the company to restore stockholders' equity to the required $2.5 million threshold.
- Confirm the current trading status of MBRX on The Nasdaq Stock Market LLC.
- Review subsequent filings for details on the financial transactions that enabled the restoration of compliance.